The 36-month beta value for SLS is at 2.37. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLS is 54.64M, and currently, shorts hold a 9.48% of that float. The average trading volume for SLS on April 02, 2024 was 1.45M shares.
SLS) stock’s latest price update
SELLAS Life Sciences Group Inc (NASDAQ: SLS) has seen a rise in its stock price by 5.61 in relation to its previous close of 1.07. However, the company has experienced a 8.65% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-01-25 that NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.
SLS’s Market Performance
SELLAS Life Sciences Group Inc (SLS) has experienced a 8.65% rise in stock performance for the past week, with a 13.00% rise in the past month, and a 6.60% rise in the past quarter. The volatility ratio for the week is 9.09%, and the volatility levels for the past 30 days are at 11.93% for SLS. The simple moving average for the past 20 days is -2.40% for SLS’s stock, with a -5.58% simple moving average for the past 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at 25.42% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.96% of loss for the given period.
Volatility was left at 11.93%, however, over the last 30 days, the volatility rate increased by 9.09%, as shares surge +8.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +112.74% upper at present.
During the last 5 trading sessions, SLS rose by +7.70%, which changed the moving average for the period of 200-days by -32.52% in comparison to the 20-day moving average, which settled at $1.1623. In addition, SELLAS Life Sciences Group Inc saw 6.60% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SLS
The total capital return value is set at 3.88. Equity return is now at value -874.00, with -271.27 for asset returns.
Based on SELLAS Life Sciences Group Inc (SLS), the company’s capital structure generated -0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -70.43. The debt to equity ratio resting at -0.06. The interest coverage ratio of the stock is 154.42.
Currently, EBITDA for the company is -37.87 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In conclusion, SELLAS Life Sciences Group Inc (SLS) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
